Collectively, consistent with the results of in vitro studies, the results confirmed that the combination of an EGFR inhibitor induced autophagy and acted synergistically to suppress the growth of primary resistant NSCLC tumors in vivo. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.